← All trials
NCT03732001
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 8, 2018
- Primary completion
- Nov 9, 2019
- Completion date
- Nov 9, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- China Medical UniversityLead sponsor
- China Medical UniversityOverall official - principal investigator
- China Medical UniversityReponsible party - principal investigator
- People's Liberation Army of ChinaCollaborator
- Shengjing HospitalCollaborator
- The First People's Hospital of JingzhouCollaborator
- Dalian Medical UniversityCollaborator
- The People's Hospital of Liaoning ProvinceCollaborator
- Shenyang Chest HospitalCollaborator
- Panjin Central HospitalCollaborator
- Liaohe Oil Field General HospitalCollaborator
- Benxi City hospital of Chinese medicineCollaborator
- Anshan Tumor HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.